Protective effect of melatonin in a non-septic shock model induced by zymosan in the rat.
In vitro studies have demonstrated that melatonin is a scavenger of oxyradicals and peroxynitrite and an inhibitor of nitric oxide (NO) production. Recently, it has been proposed that zymosan, a non-bacterial agent, causes inflammation by inducing the production of various cytokines and pro-inflammatory mediators. In the present study we evaluated the effect of melatonin treatment in a non-septic shock model induced by zymosan in the rat. Administration of zymosan (500 mg/kg intraperitoneally) in the rat induced acute peritonitis, as assessed by a marked increase in the leukocyte count in the exudate, as well as by an increase in the exudate nitrate/nitrite concentration. This inflammatory process coincided with the damage of lung, small intestine, and liver, as assessed by histological examination and by increase of myeloperoxidase activity, indicative of neutrophil infiltration. Peritoneal administration of zymosan in the rat induced also an significant increase in the plasma levels of nitrite and nitrate, stable metabolites of nitric oxide (NO), and in the levels of peroxynitrite, as measured by the oxidation of the fluorescent dye dihydrorhodamine 123, at 18 hr after zymosan challenge. Immunohistochemical examination demonstrated a marked increase in the immunoreactivity to nitrotyrosine, a specific "footprint" of peroxynitrite, in the lung of zymosan-shocked rats. Pretreatment of zymosan-shocked rats with melatonin (25 and 50 mg/kg, intraperitoneally, 5 min before zymosan) prevented in a dose dependent manner the development of peritonitis and reduced peroxynitrite formation. In addition, melatonin (50 mg/kg, intraperitoneally, 5 min before zymosan) was effective in preventing the development of organ failure since tissue injury and neutrophil infiltration, by myeloperoxidase evaluation, was reduced in lung, small intestine, and liver. Taken together, the present results demonstrate that melatonin exerts potent antiinflammatory effects.
Cuzzocrea
S
S
Institute of Pharmacology, School of Medicine, University of Messina, Italy. salvator@imeuniv.unime.it
Zingarelli
B
B
Costantino
G
G
Caputi
A P
AP
D000208:Acute Disease; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D056486:Chemical and Drug Induced Liver Injury; D002634:Chemotaxis, Leukocyte; D004305:Dose-Response Relationship, Drug; D016166:Free Radical Scavengers / Q000494:pharmacology*; D007082:Ileum / Q000187:drug effects / Q000473:pathology; D007124:Immunoenzyme Techniques; D007410:Intestinal Diseases / Q000139:chemically induced / Q000209:etiology / Q000517:prevention & control*; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology; D008107:Liver Diseases / Q000473:pathology* / Q000517:prevention & control; D008171:Lung Diseases / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D008550:Melatonin / Q000494:pharmacology*; D009504:Neutrophils; D009566:Nitrates / Q000097:blood; D009573:Nitrites / Q000097:blood; D010538:Peritonitis / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D009195:Peroxidase / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D012441:Saccharomyces cerevisiae; D015054:Zymosan
D000975:Antioxidants; D016166:Free Radical Scavengers; D009566:Nitrates; D009573:Nitrites; C039642:peroxynitric acid; D015054:Zymosan; D009195:Peroxidase; D008550:Melatonin